Abstract
The effect of topical co-administration of promoter drugs with paclitaxel to increase anti-tumor effects of paclitaxel was investigated. Mice with orthotopic 4T1-Luc breast cancer received single intra-tumoral injection of a polymeric formulation with paclitaxel and a specific promoter drug. Several promoter drugs were evaluated, including: dexamethasone, losartan, nicotinamide, Azone, and oleic acid. Dexamethasone exhibited the highest effect on paclitaxel anti-tumor activity, in a dose-dependent fashion. However, this effect was accompanied by systemic effects of dexamethasone, and inability to prevent tumor metastasis to the lungs. Topical co-administration of promoter drugs with anti-cancer agents can enhance their anti-tumor effects. Further investigations are needed to identify the most efficient combinations of promoter and anti-cancer drugs, and their suitability for the clinical management of the breast cancer disease.
| Original language | English |
|---|---|
| Pages (from-to) | 1-7 |
| Number of pages | 7 |
| Journal | Journal of Controlled Release |
| Volume | 279 |
| DOIs | |
| State | Published - 10 Jun 2018 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2018 Elsevier B.V.
Funding
This work was supported by the research grant No 2013/131 from the United States-Israel Binational Science Foundation .
| Funders | Funder number |
|---|---|
| United States-Israel Binational Science Foundation | 2013/131 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Dexamethasone
- Intra-tumoral implant
- Local anti-cancer treatment
- Orthotopic model of breast cancer
- Paclitaxel
- Promoter drugs
Fingerprint
Dive into the research topics of 'Efficacy of paclitaxel/dexamethasone intra-tumoral delivery in treating orthotopic mouse breast cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver